Possible involvement of post-dopamine D2 receptor signalling components in the pathophysiology of schizophrenia

Shirly Amar, Galit Shaltiel, Liad Mann, Alon Shamir, Brian Dean, Elizabeth Scarr, Yuly Bersudsky, R. H. Belmaker, Galila Agam

Research output: Contribution to journalArticlepeer-review

31 Scopus citations

Abstract

Par-4 has been suggested to mediate dopamine neurotransmission. Dopamine D2 receptor (DRD2) activation induces a signalling complex of AKT1, PP2A and β-arrestin2 which dephosphorylates/inactivates AKT1 thereby activating GSK-3β, transducing dopamine-dependent behaviour. DRD2 activation also results in down-regulation of PKA activity. Among other substrates PKA phosphorylates GSK-3β. Prolonged DRD2 activation leads to its 'desensitization' which involves GRKs and β-arrestins. β-arrestin1 binds to phosphorylated receptors preventing further G-protein stimulation. This study examined whether Par-4, β-arrestin1, AKT1 and GSK-3β are involved in the pathophysiology of schizophrenia. Lymphocytes obtained from schizophrenia and bipolar patients and healthy controls recruited from the Beer-Sheva Mental Health Center were transformed by Epstein-Barr virus (EBV) into lymphocyte-derived cell lines (LDCL). Post-mortem brain samples were obtained from the Rebecca L. Cooper Brain Bank, Parkville, Australia. The study was approved by the IRB committees of Beer-Sheva, Israel and Parkville, Australia. Levels of the specific proteins were assayed by Western blotting. β-arrestin1 protein levels were significantly ∼2-fold increased in LDCL from schizophrenia patients while Par-4 protein levels were unaltered. A 63% significant decrease was found in frontal cortex phospho-Ser9-GSK-3β protein levels in schizophrenia but not in those of AKT1, Par-4 or β-arrestin1. Elevated β-arrestin1 protein levels in LDCL and decreased phospho-Ser9-GSK-3β protein levels in post-mortem frontal cortex of schizophrenia patients vs. control groups support the possible involvement of these proteins in the pathophysiology of schizophrenia. However, since we did not find differences in β-arrestin1, AKT1 and Par-4 protein levels in post-mortem frontal cortex of schizophrenia patients and although GSK-3β participates in other signalling cascades we can not rule out the possibility that the differences found reflect deviation in DRD2 signalling.

Original languageEnglish
Pages (from-to)197-205
Number of pages9
JournalInternational Journal of Neuropsychopharmacology
Volume11
Issue number2
DOIs
StatePublished - 1 Mar 2008

Keywords

  • AKT1
  • Dopamine D receptors (DRD2)
  • Par-4
  • Phospho-Ser9-GSK-3β
  • Schizophrenia
  • β-arrestin1

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Possible involvement of post-dopamine D2 receptor signalling components in the pathophysiology of schizophrenia'. Together they form a unique fingerprint.

Cite this